By Inayah Entzminger at ASBMB Today | July 9, 2026
Peptide drugs offer greater surface specificity than small molecules for therapeutic applications. Making them as stable in the body as small molecules remains a major challenge. Sethera Therapeutics, a peptide biotechnology company based in Salt Lake City, Utah, aims to solve a central challenge in peptide drug discovery: designing peptides that remain stable and active in the human body.